Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Varenicline effective for smoking cessation in patients with cardiovascular disease

  • Comment

A a study that examined varenicline has found that it is a safe and effective treatment for smoking cessation in smokers with cardiovascular disease.

Researchers conducted a multicentre, randomized, double-blind, placebo-controlled trial to compare the efficacy and safety of varenicline with a placebo for smoking cessation. The study included 714 smokers with stable cardiovascular disease.

Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counselling, for 12 weeks and were followed up for 52 weeks.

The researchers found that smoking cessation was more effective with varenicline than placebo. The two groups did not differ significantly in cardiovascular mortality or cardiovascular events.

The authors note that the size of the trial and duration limit any definitive conclusions about safety.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.